Expert Interview
Discussing the use and potential of Rezurock for the treatment of Chronic Graft vs. Host disease (cGVHD)
Ticker(s): SNYInstitution: City of Hope
- Associate Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation
- Currently manages 50 patients with cGVHD and familiar with literature to date for Rezurock(Belumosudil)
- Published 40 research papers and clinical interests include management of patients with Acute Leukemia, Hematopoietic Cell Transplant and HCT related complications including acute and chronic Graft Versus Host Disease.
Please describe your clinical practice. Roughly how many patients with Chronic Graft vs. Host do you currently manage?
Added By: sara_adminWhat are your thoughts on the use of Rezurock and how does it compare to other treatment options?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited), how would you rate your level of excitement for Rezurock?
Added By: sara_adminOpportunity for Rezurock in earlier lines.
2nd line:
Will you try it out there as an alternative to 2nd line options?
Do you prefer to see trial data on that first?
Based on MOA could this be developed as prophylaxis in the much larger post-transplant setting?
What kind of new trials would you like to see or participate in with this agent?
Have you prescribed Rezurock?
Added By: user1ae2bf5fHow has clinical experience stacked up against the clinical trial data?
Similar efficacy and safety?
Are your patients responding?
How would you compare Rezurock with the competing systemic agents such as Jakafi and Imbrutinib, in terms of their relative benefits and risks?
Added By: user1ae2bf5fWhen you prescribe Rezurock, where are you placing it in the treatment paradigm? Strictly according to label? Or pushing earlier? Do you consider Jakafi/Ibrutinib "2nd line" or are those being used after 2 *other systemic treatments already failed and therefore they are 3rd line?
Is Rezurock an alternative to jakafi/ibrutinib in the setting where you usually use them?
If so, what will be the deciding factors on which patients to give which treatment?
What other approaches in development are you excited about? Either for improvement of the transplant process to prevent downstream GVHD later on, or in the setting of treating acute/chronic GVHD
Added By: user1ae2bf5fHow has the process gone with payors and getting patients access to Rezurock?
Added By: user1ae2bf5fAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
